Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma (PRNewswire) - Oct 26, 2026 - "The application is proposed to be sintilimab in combination with Nolgileucel Injection (GC101) for the treatment of patients with unresectable or metastatic melanoma whose disease has progressed following at least two lines of prior systemic therapy, including PD-1 antibody therapy....The new indication application is primarily based on the results of the pivotal Phase II clinical study MIZAR-003."
China filing • Melanoma
|